Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pimco Energy and Tactical Opportunities Fund (NRGX)

Pimco Energy and Tactical Opportunities Fund (NRGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pimco Energy and Tactical Opportunities Fund

Description:

Neurologix, Inc. is a Delaware Corporation. It is a development stage company that is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, using gene transfer and other innovative therapies. These treatments are designed as alternatives to conventional surgical and pharmacological treatments. The Company's development efforts are currently focused on gene transfer for treating Parkinson's disease. Its core technology, which it refers to as 'NLX,' is in the clinical development stages and was tested in a Phase 1 and Phase 2 clinical trials to treat Parkinson's disease. Although the Company's operations and resources will be mainly concentrated on its Parkinson's disease therapy, the Company intends to continue to develop therapies to treat other neurodegenerative and metabolic disorders, including therapies relating to epilepsy and Huntington's disease. It faces intense competition from pharmaceutical companies, biotechnology companies, universities, governmental entities and other healthcare providers developing alternative treatments for Parkinson's disease, Huntington's disease and epilepsy.

Key Statistics

Overview:

Annual Sales, $ 184,616 K
Annual Net Income, $ -10,160 K
Short Volume Ratio 0.32

Growth:

1-Year Return 30.29%
3-Year Return 154.20%
5-Year Return 0.00%

Per-Share Information:

Next Earnings Date 03/23/12
EPS Growth vs. Prev Year 1.36%
Next Ex-Dividends Date 09/08/23
Dividend Payable Date 10/02/23
Dividend Payout Ratio 21.31%

NRGX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 100.03%
Debt/Equity 0.18
Price/Sales 4.91
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 18.49
Interest Coverage N/A

NRGX Dividends

Date Value
09/08/23 $0.2200
06/09/23 $0.2200
03/10/23 $0.2200
12/09/22 $0.2200
09/09/22 $0.2200
06/10/22 $0.2200
03/10/22 $0.2200
12/10/21 $0.1700
09/10/21 $0.1700
06/10/21 $0.1700
03/10/21 $0.1700
12/10/20 $0.1700
09/10/20 $0.1700
06/10/20 $0.4000
03/11/20 $0.4000
12/13/19 $0.2800
12/11/19 $0.4000
09/12/19 $0.4000
06/12/19 $0.4000
03/29/19 $0.1000
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar